title: Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles.
abstract: Recent studies have documented the importance of Niemann-Pick C1-like 1 protein (NPC1L1), a putative physiological target of the drug ezetimibe, in mediating intestinal cholesterol absorption. However, whether NPC1L1 is the high affinity cholesterol binding protein on intestinal brush border membranes is still controversial. In this study, brush border membrane vesicles (BBMV) from wild type and NPC1L1-/- mice were isolated and assayed for micellar cholesterol binding in the presence or absence of ezetimibe. Results confirmed the loss of the high affinity component of cholesterol binding when wild type BBMV preparations were incubated with antiserum against the class B type 1 scavenger receptor (SR-BI) in the reaction mixture similar to previous studies. Subsequently, second order binding of cholesterol was observed with BBMV from wild type and NPC1L1-/- mice. The inclusion of ezetimibe in these in vitro reaction assays resulted in the loss of the high affinity component of cholesterol interaction. Surprisingly, BBMVs from NPC1L1-/- mice maintained active binding of cholesterol. These results documented that SR-BI, not NPC1L1, is the major protein responsible for the initial high affinity cholesterol ligand binding process in the cholesterol absorption pathway. Additionally, ezetimibe may inhibit BBM cholesterol binding through targets such as SR-BI in addition to its inhibition of NPC1L1.
authors: Department of Pathology (ML0507), Genome Research Institute, University of Cincinnati, 2120 E. Galbraith Rd., Cincinnati, OH 45237, USA.
authors: Eric D
authors: ED
authors: Labonté
authors: Philip N
authors: PN
authors: Howles
authors: Norman A
authors: NA
authors: Granholm
authors: Juan C
authors: JC
authors: Rojas
authors: Joanna P
authors: JP
authors: Davies
authors: Yiannis A
authors: YA
authors: Ioannou
authors: David Y
authors: DY
authors: Hui
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000737:chemistry / Q000494:pharmacology*; D016632:Apolipoprotein A-I / Q000494:pharmacology; D001384:Azetidines / Q000737:chemistry / Q000494:pharmacology*; D002784:Cholesterol / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008823:Micelles; D008871:Microvilli / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D051122:Scavenger Receptors, Class B / Q000235:genetics / Q000378:metabolism*; D022161:Transport Vesicles / Q000378:metabolism*
chemical_list: D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D001384:Azetidines; D026901:Membrane Transport Proteins; D008823:Micelles; C482445:Npc1l1 protein, mouse; C454739:Scarb1 protein, mouse; D051122:Scavenger Receptors, Class B; D002784:Cholesterol; D000069438:Ezetimibe